Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Time:2018-09-21Source : AmoyDx
Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.

Important Leads:

◎ AmoyDx Essential NGS Panel: Focused on 10 oncogenes approved by FDA for targeted drugs.

◎ Super-ARMS EGFR: Significant improvement on qPCR platform of liquid biopsy EGFR testing.

For more information, please call us at +86-592-6806835 or email us at sales@amoydx.com.



Tel:+86-592-6806835
Email:sales@amoydx.com
BACK
Recommend
AmoyDx and PREMIA Jointly Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network
25 /06
Breaking News! ROS1, EGFR included on health insurance list of SK, TW
24 /06
Visit AmoyDx at AMP Global Congress 2019 in Hong Kong
30 /04
Visit AmoyDx at European Lung Cancer Congress 2019 in Geneva
27 /03
Visit AmoyDx at AACR Annual Meeting 2019 in Atlanta, USA
26 /03
AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit approved by Chinese Authority
01 /03
Welcome to visit AmoyDx on 17th Congress on Targeted Anticancer Therapies (TAT) in Paris
26 /02
Sanomics Limited and Amoy Diagnostics Partner to Deliver Multi-Gene Tests in Hong Kong and Macau
28 /01
AmoyDx ROS1 Kit Approval in Taiwan
18 /12
AmoyDx® Essential NGS panel approval from Chinese authority
21 /11
2018 AmoyDx Distributors Annual Meeting successfully held in Shanghai
11 /11
Visit AmoyDx at AMP Annual Meeting 2018 in USA
02 /11
AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib
10 /10
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
21 /09
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
24 /08
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
04 /04
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
22 /01
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
05 /12
AmoyDx Distributors Annual Meeting (Europe) 2017
20 /11
Visit AmoyDx at MEDICA 2017, Germany
17 /11
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
20 /10
Visit AmoyDx at MEDICA 2017 in Germany
20 /10
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
20 /09
Visit AmoyDx at WCLC 2017 of IASLC in Japan
16 /08
Amoy Diagnostics Co., Ltd. achieved IPO on Shenzhen Stock Exchange
02 /08
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
28 /06
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
22 /05
AmoyDx in European Lung Cancer Conference (ELCC) 2017
09 /05
Visit AmoyDx at ELCC 2017 in Switzerland
21 /04
AmoyDx HER2 Mutation Test Acting as Companion Diagnostics for Boehringer Ingelheim's Afatinib Study in NSCLC Patients
14 /02
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
03 /02
TOP
Inquiry
* Required information
Manage your account info
Change your password